Amesite is expected to report its fiscal first-quarter 2027 results on October 30, 2026, for the period ending September 30. While analysts have not established a formal consensus for revenue or EPS this quarter, the stock holds an average analyst price target of $7.14 against a current price of approximately $0.60.
Investors are primarily focused on the commercial traction and user growth of the NurseMagic AI platform following its shift to a new $1,099 monthly minimum enterprise pricing model.
This report follows a strong fiscal 2026 performance where the company achieved a 2.4x sequential quarterly revenue increase and 230% year-over-year annual growth. Management's ability to convert its B2B pipeline into scalable recurring revenue remains the central narrative for investors watching this healthcare-AI pivot.